vaccines Archives -

News/ News/ R&D

Merck makes circular RNA play with $3.5bn Orna alliance

Phil Taylor circular RNA, Merck & Co, Oncology, Orna Therapeutics, partnering, rna, vaccines 0 Comment

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics

Merck makes circular RNA play with $3.5bn Orna alliance

https://pharmaphorum.com/news/merck-makes-circular-rna-play-with-3-5bn-orna-alliance/

News/ News/ Patients

COVID antibody declines prompts call for booster jabs ASAP

Phil Taylor coronavirus, COVID-19, patients, UK, vaccines 0 Comment

Figures from the UK Office for National Statistics (ONS) have revealed that the number of people with higher

COVID antibody declines prompts call for booster jabs ASAP

https://pharmaphorum.com/news/covid-antibody-declines-prompts-call-for-booster-jabs-asap/

News/ News/ R&D

Ex-GSK vaccine chief to lead new UK biotech Vicebio

Phil Taylor GlaxoSmithKline, respiratory syncytial virus, vaccines, Vicebio 0 Comment

GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called

Ex-GSK vaccine chief to lead new UK biotech Vicebio

https://pharmaphorum.com/news/ex-gsk-vaccine-chief-to-lead-new-uk-biotech-vicebio/

R&D/ Views & Analysis/ Views and analysis

New countries stockpile antiviral TPOXX as monkeypox outbreak continues

Jonah Comstock monkeypox, orthopox, Philip Gomez, SIGA technologies, vaccines 0 Comment

pharmaphorum editor in chief Jonah Comstock talks to Philip Gomez, CEO of Siga Technologies, about how his company’s

New countries stockpile antiviral TPOXX as monkeypox outbreak continues

https://pharmaphorum.com/r-d/new-countries-stockpile-antiviral-tpoxx-as-monkeypox-outbreak-continues/

News/ News/ Patients

As cases rise, WHO says monkeypox risk is “moderate”

Phil Taylor antiviral, monkeypox, public health, Smallpox, vaccines, World Health Organisation 0 Comment

The World Health organisation’s latest assessment of the monkeypox outbreak is that it poses a moderate threat to

As cases rise, WHO says monkeypox risk is “moderate”

https://pharmaphorum.com/news/as-cases-rise-who-says-monkeypox-risk-is-moderate/

Patients/ Views & Analysis/ Views and analysis

Studying inequities throughout the pandemic

Jessica Hagen COVID-19, vaccines, WHO, world health organization 0 Comment

Alain Labrique, PhD, professor and associate chair of research at Johns Hopkins Bloomberg School of Public Health (JHSPH)

Studying inequities throughout the pandemic

https://pharmaphorum.com/patients/studying-inequities-throughout-the-pandemic/

R&D/ Views & Analysis/ Views and analysis

Beyond the pandemic: the potential of mRNA technology

Ben Hargreaves BioNTech, COVID-19, Moderna, mRNA, Pfizer, vaccines 0 Comment

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the

Beyond the pandemic: the potential of mRNA technology

https://pharmaphorum.com/r-d/beyond-the-pandemic-the-potential-of-mrna-technology/

News/ News/ R&D

GSK poaches Pfizer exec Dormitzer as new vaccines R&D chief

Phil Taylor GlaxoSmithKline, Pfizer, senior management, vaccines 0 Comment

GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a

GSK poaches Pfizer exec Dormitzer as new vaccines R&D chief

https://pharmaphorum.com/news/gsk-poaches-pfizer-exec-dormitzer-as-new-vaccines-chief/

News/ News/ R&D

AstraZeneca makes a big RNA play, teaming up with VaxEquity

Phil Taylor AstraZeneca, Imperial College, rna, saRNA, vaccines, VaxEquity 0 Comment

AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of

AstraZeneca makes a big RNA play, teaming up with VaxEquity

https://pharmaphorum.com/news/astrazeneca-makes-a-big-rna-play-teaming-up-with-vaxequity/

Trending

vaccines

Login